niclosamide sodium salt

Modify Date: 2024-01-11 23:47:58

niclosamide sodium salt structure	Common Name	niclosamide sodium salt
	CAS Number	40321-86-6	Molecular Weight	349.10100
	Density	N/A	Boiling Point	N/A
	Molecular Formula	C₁₃H₇Cl₂N₂NaO₄	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of niclosamide sodium salt

Niclosamide (BAY2353) sodium is an orally active antihelminthic agent used in parasitic infection research[1]. Niclosamide sodium is a STAT3 inhibitor with an IC50 of 0.25 μM in HeLa cells[4]. Niclosamide sodium has biological activities against cancer, and inhibits DNA replication in Vero E6 cells[2][3][5].

Name	niclosamide sodium salt

Description	Niclosamide (BAY2353) sodium is an orally active antihelminthic agent used in parasitic infection research[1]. Niclosamide sodium is a STAT3 inhibitor with an IC50 of 0.25 μM in HeLa cells[4]. Niclosamide sodium has biological activities against cancer, and inhibits DNA replication in Vero E6 cells[2][3][5].
Related Catalog	Signaling Pathways >> Stem Cell/Wnt >> STAT Research Areas >> Cancer Research Areas >> Infection Signaling Pathways >> JAK/STAT Signaling >> STAT
In Vitro	Niclosamide sodium (0.6 nM-46 µM) treatment inhibits adrenocortical carcinoma cellular proliferation in BD140A, SW-13, and NCI-H295R cells[3]. Niclosamide sodium (0.05-5 μM, 24 h) treatment inhibits STAT3-mediated luciferase reporter activity in HeLa cells[4]. Niclosamide sodium (10 μM) treatment inhibits virus replication in Vero E6 cells[5]. Cell Viability Assay[3] Cell Line: BD140A, SW-13 and NCI-H295R cells Concentration: 0.6 nM-46 µM Incubation Time: Result: Inhibited cellular proliferation in adrenocortical carcinoma cell lines with the IC50 of 0.12 µM, 0.15 µM, and 0.53 µM in BD140A, SW-13, and NCI-H295R, respectively. Cell Viability Assay[4] Cell Line: Hela cells Concentration: 0.05-5 μM Incubation Time: 24 hours Result: Inhibited STAT3-mediated luciferase reporter activity with an IC50 of 0.25 μM. Western Blot Analysis[5] Cell Line: Vero E6 cells Concentration: 10 μM Incubation Time: 2 days Result: Inhibited the synthesis of viral antigens of SARS-CoV in Vero E6 cells.
In Vivo	Niclosamide sodium (oral gavage; 100 mg/kg, 200 mg/kg; once a week; 8 weeks) treatment inhibits adrenocortical carcinoma tumor growth in vivo[3]. Animal Model: Nu+/Nu+ mice injected with NCI-H295R cells[3] Dosage: 100 mg/kg, 200 mg/kg Administration: Oral gavage; 100 mg/kg, 200 mg/kg; once a week; 8 weeks Result: Showed a 60%-80% inhibition in tumor growth, as compared to the control group.
References	[1]. P Andrews, et al. The biology and toxicology of molluscicides, Bayluscide. Pharmacol Ther. 1982;19(2):245-95. [2]. Wei Chen, et al. Niclosamide: Beyond an antihelminthic drug. Cell Signal. 2018 Jan;41:89-96. [3]. Kei Satoh, et al. Identification of Niclosamide as a Novel Anticancer Agent for Adrenocortical Carcinoma. Clin Cancer Res. 2016 Jul 15;22(14):3458-66. [4]. Xiaomei Ren, et al. Identification of Niclosamide as a New Small-Molecule Inhibitor of the STAT3 Signaling Pathway. ACS Med Chem Lett. 2010 Sep 7;1(9):454-9. [5]. Chang-Jer Wu, et al. Inhibition of severe acute respiratory syndrome coronavirus replication by niclosamide. Antimicrob Agents Chemother. 2004 Jul;48(7):2693-6.

Molecular Formula	C₁₃H₇Cl₂N₂NaO₄
Molecular Weight	349.10100
Exact Mass	347.96800
PSA	97.98000
LogP	4.89390

niclosamide sodium salt

Use of niclosamide sodium salt

Names

niclosamide sodium salt Biological Activity

Chemical & Physical Properties